Fevertree Drinks (FEVR) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
12 Sep, 2025Executive summary
Product diversification and strong brand momentum are driving growth across all major regions, with significant expansion beyond tonic water and broadening consumption occasions.
The transformational partnership with Molson Coors in the US is progressing well, enhancing distribution, marketing, and operational efficiency, and providing exclusive US rights.
Robust financial performance is underpinned by strong cash generation, a £30m share buyback extension into 2026, and comfort with full-year market expectations.
Product diversification, especially ginger beer and premium soft drinks, now represents up to 45% of group revenues and is deepening consumer relevance.
Full-year expectations remain unchanged, with a robust start to the second half and positive momentum across all regions.
Financial highlights
Adjusted revenue for H1 FY25 was £172.2m, up 12% at constant currency; US segment revenue grew 6%, UK declined 6%, Europe was flat, and Rest of World grew 17%.
Adjusted EBITDA was £18.4m, up 1% year-over-year, with a margin of 10.7%, and Rest of Group segment achieved a 23.8% margin, up 540bps.
Cash position increased to £130m, up 67% year-over-year, supporting an expanded share buyback program.
Working capital reduced to 16.7% of adjusted revenue, aiding strong cash generation.
Diluted EPS increased 5% to 6.82p; interim dividend up 2% to 5.97p per share.
Outlook and guidance
Revenue guidance for the year remains unchanged, with low single-digit adjusted revenue growth expected and short-term EBITDA impact from the US transition.
H2 EBITDA margin expected to benefit from central cost leverage, with US transition and FX headwinds to continue.
Confident in medium-term strong revenue and EBITDA growth, driven by US acceleration and operational efficiencies from the Molson Coors partnership.
UK and Europe expected to return to growth as tonic category stabilizes and portfolio diversification scales.
Continued focus on product diversification and operational improvements to drive long-term growth.
Latest events from Fevertree Drinks
- FY25 revenue and EBITDA to surpass expectations, with robust US and global growth.FEVR
Trading update29 Jan 2026 - 79% EBITDA growth and 520bps margin gain in H1, with strong US and global share gains.FEVR
H1 202420 Jan 2026 - Molson Coors takes 8.5% stake, US operations, and guarantees royalties for accelerated growth.FEVR
Partnership9 Jan 2026 - Robust FY24 growth, margin recovery, and U.S. partnership drive future gains.FEVR
H2 202424 Dec 2025 - Fever-Tree delivers market share gains and reaffirms full year outlook with global growth.FEVR
Trading Update13 Jun 2025 - Strong US growth, UK leadership, and robust capital returns mark Fever-Tree's 2025 update.FEVR
Trading Update9 Jun 2025